Abstract 1859P
Background
Cognitive impairment (CI) is a common late effect after cancer treatment, for which effective treatment is lacking. Goal Management Training (GMT) is a validated cognitive remediation protocol reported to improve cognition including perceived daily life executive functioning, in neurological conditions. However, GMT has never been examined in cancer survivors, nor been presented in a digital format. This study examined the feasibility and acceptability of digital GMT in cervical cancer survivors (CCS) with subjective and/or objective CI.
Methods
We invited 65 CCS with CI to participate. Participants were randomized in a 1:1 ratio between digital GMT and a computerized cognitive training (CCT) program (BrainHQ). GMT consists of six weekly group-based modules encompassing discussion of participants’ real-life cognitive deficits, practice on tasks of attention and self-monitoring, as well as homework assignments. BrainHQ is a web-based training platform with exercises targeting several cognitive domains. For six weeks, participants joined digital training sessions of one hour twice a week. The primary endpoint was attendance, and participants attending ≥80% of the sessions were categorized as completers. Acceptability was evaluated 1 week post-intervention using the Client Satisfaction Questionnaire-8 (CSQ-8). A total CSQ-8 score ≥ 26 was defined as “very satisfied”, scores 20-25 as “satisfied”, and scores <20 as “not satisfied”.
Results
33 CCS with a median age of 50.0 years (range 35-67) were randomized to either GMT (N = 16) or CCT (N = 17). In the GMT group, all participants completed the intervention (100%), compared to 15 (88%) in the CCT group. Median CSQ-8 in the GMT and CCT group was 25 (SD 3.7, range 18-31) and 24 (SD 3.1, range 19-30) respectively. Participants in both groups reported a high level of satisfaction as 40% reported being “very satisfied” and 53% “satisfied”.
Conclusions
A digital cognitive training program such as GMT is feasible with a high level of compliance and satisfaction in CCS and is suitable to be tested in a larger study. Exploratory analyses of neuropsychological assessments in our study will provide important preliminary data on the efficacy of improving cognitive function in CCS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jan Kåre Heiberg and Marthe Vildåsen.
Disclosure
K. lindemann: Financial Interests, Institutional, Research Grant, Grants or contracts, paid to institution: GSK; Financial Interests, Institutional, Advisory Board, Participation on Data Safety Monitoring/advisory board: Eisai, MSD, Nycode, AstraZeneca, GSK. All other authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05